在科创板生物医药板块2026年一季度业绩披露落下帷幕之际,一组振奋人心的财务数据随之定格。数据显示,科创板28家创新药企业2025年合计营收约740亿元,同比增长近30%;行业净利润约16亿元,首次实现整体盈利。 在行业整体向好的背景下,诺诚健华(688428.SH/09969.HK)表现尤为亮眼。数据显示,诺诚健华继2025年首次实现年度盈利后,本季度营收5.29亿元,同比增长38.65%,...
Source Link在科创板生物医药板块2026年一季度业绩披露落下帷幕之际,一组振奋人心的财务数据随之定格。数据显示,科创板28家创新药企业2025年合计营收约740亿元,同比增长近30%;行业净利润约16亿元,首次实现整体盈利。 在行业整体向好的背景下,诺诚健华(688428.SH/09969.HK)表现尤为亮眼。数据显示,诺诚健华继2025年首次实现年度盈利后,本季度营收5.29亿元,同比增长38.65%,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.